TG4010

Summary of Presentations from the 11th Targeted Therapies for Lung Cancer Meeting; Immunotherapy and Vaccines for Treatment of Lung Cancer

(2011) Peter Ujhazy et al.   Journal of Thoracic Oncology

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

(2011) Elisabeth Quoix et al.   LANCET ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

(2010) Stéphane Oudard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

(2008) R. Dreicer et al.   INVESTIGATIONAL NEW DRUGS

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY